TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24903131

Group type: EXPERIMENTAL
Intervention: Nebulised budesonide (800 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nebulised budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 0
Study: 23945072

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Pegfilgrastim (control group)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim (experimental group)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim
Number of subjects: 202

Group type: COMPARATOR
Intervention: Pegfilgrastim
Number of subjects: 202
Study: 21773781

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) with starting dose of 75-100 IU daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) at 100 mg/day for 5 days
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 189
Study: 19341123

Group type: EXPERIMENTAL
Intervention: Hyperbaric treatment group (33 patients)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham control group (39 patients)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 72
Study: 15976213

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study: 12598346

Group type: EXPERIMENTAL
Intervention: Anthracycline-based neoadjuvant chemotherapy
Number of subjects: 448
Study: 10047639

Group type: EXPERIMENTAL
Intervention: Furosemide (40 to 60 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Azosemide (60 to 90 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Azosemide
Number of subjects: 19
Study: 7762839

Group type: EXPERIMENTAL
Intervention: Ketorolac (0.9 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline placebo (2 mL)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram/kg)
Number of subjects: 54
Study: 2137888

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CSA)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7000260

Group type: EXPERIMENTAL
Intervention: Single daily injections of insulin (Monotard plus Actrapid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Twice-daily injections of insulin (Semitard plus Actrapid)
Number of subjects: 15
Study: 11974458

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for palliation by ablation, dilatation, or stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of postoperative complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of anastomotic strictures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional flexible endoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficient detection of locoregional recurrence
Number of subjects: 0
Study: 30252113

Group type: EXPERIMENTAL
Intervention: Life stress interview (90 minutes)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No interview (treatment-as-usual control)
Number of subjects: 62
Study: 29784890

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 172
Study: 26646854

Group type: EXPERIMENTAL
Intervention: Code-word alarm
Number of subjects: 353

Group type: COMPARATOR
Intervention: Control (commercially available wireless alarm)
Number of subjects: 353
Study: 24866527

Group type: EXPERIMENTAL
Intervention: Maternal vocal responses to moral transgressions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Maternal vocal responses to prudential transgressions
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Maternal vocal responses to pragmatic transgressions
Number of subjects: 2
Study: 23074932

Group type: EXPERIMENTAL
Intervention: Monopolar TUR
Number of subjects: 198

Group type: COMPARATOR
Intervention: Quasibipolar TUR
Number of subjects: 198
Study: 20446503

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal Training (NT)
Number of subjects: 0
Study: 17512015

Group type: EXPERIMENTAL
Intervention: N2O and oxygen inhalation (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Air and oxygen mixture (group 2)
Number of subjects: 28
Study: 16240961

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (PLP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adper (AD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 35% phosphoric acid (control)
Number of subjects: 32
Study: 11906359

Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous birch pollen immunotherapy (IT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 35
Study: 10434231

Group type: EXPERIMENTAL
Intervention: Valganciclovir 360 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral ganciclovir 1000 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous ganciclovir 5 mg/kg
Number of subjects: 18
Study: 7573783

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2140848

Group type: EXPERIMENTAL
Intervention: Oral loading with L-tryptophan
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant treatment
Number of subjects: 25
Study: 375865

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine (Thorazine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31064974

Group type: COMPARATOR
Intervention: Control Group (CP adjusted every 30 minutes using N₂O)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (CP adjusted every 10 minutes using N₂O)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (non‐adjusted CP using air)
Number of subjects: 84
Study: 28763350

Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting of the radial artery
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional harvesting of the radial artery
Number of subjects: 119
Study: 25456867

Group type: EXPERIMENTAL
Intervention: Prolastin C (human plasma-derived AAT) at 60 mg/kg infused intravenously within 12 hours of admission
Number of subjects: 10
Study: 24035369

Group type: EXPERIMENTAL
Intervention: Liquid adhesive ocular bandage (Ocuseal)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10‐0 nylon suture
Number of subjects: 90

Group type: COMPARATOR
Intervention: No additional treatment (control)
Number of subjects: 90
Study: 21853425

Group type: EXPERIMENTAL
Intervention: Oral itraconazole (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fluconazole nasal spray (group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined oral itraconazole and nasal fluconazole (group C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irrigation with fluconazole solution (group D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Convenient medical treatment only (group E)
Number of subjects: 50
Study: 19663129

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI, 80/4.5 microg (320/18 microg/d) twice daily
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI, 160/4.5 microg (320/9 microg/d) once daily
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI, 80/4.5 microg (160/9 microg/d) once daily
Number of subjects: 619

Group type: COMPARATOR
Intervention: Budesonide pMDI, 160 microg (320 microg/d) once daily
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 619
Study: 16323085

Group type: EXPERIMENTAL
Intervention: Famciclovir (1000 mg given twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12872795

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (Nerve Fiber Analyzer [NFA] GDx) in patients with PDS
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (Nerve Fiber Analyzer [NFA] GDx) in patients with PG
Number of subjects: 56
Study: 10807120

Group type: EXPERIMENTAL
Intervention: Citric acid demineralization
Number of subjects: 36

Group type: COMPARATOR
Intervention: No citric acid demineralization (Control)
Number of subjects: 36
Study: 8880078

Group type: EXPERIMENTAL
Intervention: 25 micrograms CCK4
Number of subjects: 12
Study: 1824707

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol (Estraderm; 0, 50, 100, or 150 micrograms/day) combined with oral medroxyprogesterone acetate (10 mg each day) during weeks 3-4 and 7-8 of each 8-week regimen
Number of subjects: 28
Study: 6851041

Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day)
Number of subjects: 13
Study: 30628953

Group type: EXPERIMENTAL
Intervention: Shanghai growth standards (S-group)
Number of subjects: 15019

Group type: COMPARATOR
Intervention: WHO 2006 growth standards (W-group)
Number of subjects: 15019
Study: 28746186

Group type: EXPERIMENTAL
Intervention: Laparoscopic-based PIV score assessment with MDT for patients with PIV <8
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chemotherapy alone for patients with PIV >=8
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall survival for optimal cytoreduction
Number of subjects: 58
Study: 25985858

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pseudo-neurofeedback
Number of subjects: 20
Study: 23288870

Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe 10/10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 50
Study: 22024001

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 89
Study: 19405936

Group type: EXPERIMENTAL
Intervention: Radiation therapy with concurrent chemotherapy (docetaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 0
Study: 16922703

Group type: EXPERIMENTAL
Intervention: Moderate daily amount of red wine
Number of subjects: 115

Group type: COMPARATOR
Intervention: No red wine (control group)
Number of subjects: 115
Study: 15130225

Group type: EXPERIMENTAL
Intervention: remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 60
Study: 11471853

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg/day)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Zopiclone (7.5 mg/day)
Number of subjects: 479
Study: 9737456

Group type: EXPERIMENTAL
Intervention: Standard thickness (STD) ePTFE grafts
Number of subjects: 108

Group type: COMPARATOR
Intervention: Thin wall (THN) ePTFE grafts
Number of subjects: 108
Study: 8291963

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (50, 75, or 100 micrograms)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (programmable pump and intrathecal catheter)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (high doses > 1,000 micrograms/d)
Number of subjects: 23
Study: 3174151

Group type: EXPERIMENTAL
Intervention: Epidural morphine 5 mg in 5 ml of saline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 micrograms in 5 ml of saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 20
Study: 31516025

Group type: EXPERIMENTAL
Intervention: Coencapsulated FTC/TDF
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Coencapsulated TFV
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Coencapsulated BIC/FTC/TAF
Number of subjects: 49

Group type: COMPARATOR
Intervention: Unencapsulated formulations
Number of subjects: 49
Study: 29420164

Group type: EXPERIMENTAL
Intervention: Apalutamide (240 mg per day)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 28608540

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 82
Study: 25091471

Group type: EXPERIMENTAL
Intervention: Text messaging intervention for 7 days
Number of subjects: 129
Study: 22927165

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg taken four times a day for 1 week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No ibuprofen
Number of subjects: 28
Study: 21626222

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) at an initial dose of 5 mg/kg for 12 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Methylprednisolone (MP) 3 pulses of 30 mg/kg followed by prednisone for 4 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (identical treatment without randomization)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Follow-up after mean 6.1 years
Number of subjects: 24
Study: 18509712

Group type: EXPERIMENTAL
Intervention: Model-based RSA with contour reduction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Marker-based RSA
Number of subjects: 24
Study: 16545474

Group type: EXPERIMENTAL
Intervention: Single fraction radiotherapy (8 Gy)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Multiple fraction radiotherapy (24 Gy in six fractions)
Number of subjects: 320
Study: 11790211

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 449
Study: 10430735

Group type: EXPERIMENTAL
Intervention: Aerosolized prostaglandin (PG)I(2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled NO
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous PGI(2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Systemic calcium antagonists (CAAs)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long-term therapy with aerosolized iloprost
Number of subjects: 8
Study: 7582384

Group type: EXPERIMENTAL
Intervention: Dispersible diclofenac (100 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enteric-coated diclofenac (100 mg)
Number of subjects: 12
Study: 2262369

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy (72 Gy in 5 weeks, 1.6 Gy per fraction, 45 fractions)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional radiotherapy (70‐72 Gy in 7‐8 weeks, 1.8‐2.0 Gy per fraction, 35‐40 fractions)
Number of subjects: 260
Study: 399090

Group type: EXPERIMENTAL
Intervention: Synalar cream (fluocinolone acetonide 0.025%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortoderm ointment (fluocinolone acetonide 0.025%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6141575

Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: whole group
Number of subjects: 49
Study: 31140297

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year after trastuzumab-based adjuvant therapy
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo for 1 year after trastuzumab-based adjuvant therapy
Number of subjects: 341
Study: 30305078

Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing and cognitive behaviour therapy (MI-CBT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (education session only)
Number of subjects: 72
Study: 27292765

Group type: EXPERIMENTAL
Intervention: 0.0015% PF tafluprost
Number of subjects: 190

Group type: COMPARATOR
Intervention: 0.5% PF timolol
Number of subjects: 190
Study: 24991733

Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg
Number of subjects: 21
Study: 22992357

Group type: EXPERIMENTAL
Intervention: Family Healthware
Number of subjects: 3786

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3786
Study: 21139557

Group type: EXPERIMENTAL
Intervention: Topical corticotherapy with mometasone furoate ointment applied once daily for 4 weeks + emollient cream applied twice a day for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical corticotherapy with mometasone furoate ointment applied once daily for 4 weeks
Number of subjects: 40
Study: 17391164

Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg/day
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg/day
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 15654072

Group type: EXPERIMENTAL
Intervention: Naturally cycling women on day 12 of their menstrual cycle
Number of subjects: 48

Group type: COMPARATOR
Intervention: Premenopausal women taking a combined monophasic oral contraceptive
Number of subjects: 48

Group type: COMPARATOR
Intervention: Men (pseudo-cycle)
Number of subjects: 48
Study: 12236025

Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography (n=64)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (n=63)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dipyridamole perfusion scintigraphy (n=61)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Severity and extent of ischemia during dipyridamole/dobutamine stress tests
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: High-risk category
Number of subjects: 188
Study: 10416734

Group type: EXPERIMENTAL
Intervention: 50 g anhydrous dextrose plus 4 mg sodium saccharin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 23.7 mg saccharin alone
Number of subjects: 0
Study: 7749424

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2397369

Group type: EXPERIMENTAL
Intervention: House physicians using the questionnaire
Number of subjects: 150

Group type: COMPARATOR
Intervention: House physicians using unstructured questions
Number of subjects: 150
Study: 7437263

Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (doses of 16, 32, 48, and 64 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (100 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone (all doses)
Number of subjects: 100
Study: 31076261

Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg or 150 mg every 2 weeks
Number of subjects: 4880

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4880
Study: 29899426

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once/day (group A)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Levofloxacin 200 mg twice/day (group B)
Number of subjects: 400
Study: 27097864

Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no SDF)
Number of subjects: 12
Study: 25699389

Group type: EXPERIMENTAL
Intervention: Ulinastatin-containing contrast medium
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control arm (same contrast medium without Ulinastatin)
Number of subjects: 280
Study: 22523090

Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Kinesio Taping
Number of subjects: 80
Study: 20055751

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (ACE 12 mg; 3 mg every 3 months and 2 mg every 2 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily oral ibandronate (ACE 5.5 mg; 2.5 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (ACE 12 mg)
Number of subjects: 0
Study: 17394255

Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of 0.6 mg/kg dexamethasone
Number of subjects: 174
Study: 16360965

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/day for ≤75 kg or 100 mg/day for >75 kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12858465

Group type: EXPERIMENTAL
Intervention: Child Health Questionnaire (CHQ)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Matched controls (n = 116)
Number of subjects: 116
Study: 10082498

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8524976

Group type: EXPERIMENTAL
Intervention: 30-min cigarette spacing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 60-min cigarette spacing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 120-min cigarette spacing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 360-min cigarette spacing (single cigarette at end of session)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Abstinence for fewer than 3 hours
Number of subjects: 10
Study: 2405555

Group type: EXPERIMENTAL
Intervention: Ionic high-osmolar contrast medium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-ionic low-osmolar contrast medium
Number of subjects: 100
Study: 7317308

Group type: EXPERIMENTAL
Intervention: Behaviour therapy with Imipramine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Behaviour therapy with placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Supportive therapy with Imipramine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 126
Study: 31369961

Group type: EXPERIMENTAL
Intervention: Navigated patellar resurfacing
Number of subjects: 20
Study: 29781483

Group type: EXPERIMENTAL
Intervention: Fish oil 0.31 g d‐1
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fish oil 0.62 g d‐1
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Fish oil 1.24 g d‐1
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 201
Study: 26707220

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine (PCV/PPV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPV) only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PCV/PPV
Number of subjects: 100